Please login to the form below

Not currently logged in
Email:
Password:

WuXi closes IPO

WuXi PharmaTech closes its initial public offering of 15,167,326 American Depositary Shares, including 1,978,347 ADSs issued in connection with the exercise of the over-allotment option in full

WuXi PharmaTech, a Chinese-headquartered pharmaceutical and biotechnology R&D outsourcing company has closed its initial public offering (IPO) of 15,167,326 American Depositary Shares ("ADSs"), including 1,978,347 ADSs issued in connection with the exercise of the over-allotment option in full.

WuXi PharmaTech's commenced trading on the New York Stock Exchange on 9 August 2007 under the symbol "WX". The US Securities and Exchange Commission (SEC) declared WuXi PharmaTech's registration statement effective.

Credit Suisse Securities (USA) and JP Morgan Securities acted as lead underwriters and joint book-runners and Jefferies & Company was co-manager in the offering.

15th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics